Lead Product(s) : PMN310
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) that are believed to be a major driver of alzheimer’s disease.
Product Name : PMN310
Product Type : Antibody
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : PMN310
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rotigotine
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : $3.9 million
Deal Type : Private Placement
Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
Details : The Company intends to use the net proceeds to fund its research, development, and commercialization activities of its drug canditates, including Rotigotine, a non-ergoline dopamine agonist approved for the treatment of Parkinson's disease and restless l...
Product Name : ROV045
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 28, 2023
Lead Product(s) : Rotigotine
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : $3.9 million
Deal Type : Private Placement
Lead Product(s) : Rotigotine
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : $3.9 million
Deal Type : Private Placement
Bionxt Solutions Announces Closing of First Tranche of Non-Brokered Private Placement
Details : The Company intends to use the net proceeds from the offering, including the first tranche, to fund its research, development, and commercialization activities of rotigotine and for general working capital purposes.
Product Name : ROV045
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 28, 2023
Lead Product(s) : Rotigotine
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : $3.9 million
Deal Type : Private Placement
Lead Product(s) : PMN310
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Affinity Asset Advisors
Deal Size : $20.4 million
Deal Type : Private Placement
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
Details : The net proceeds are expected to be used to advance the clinical development of ProMIS’ lead therapeutic candidate, PMN310, a monoclonal therapeutic antibody designed for the treatment of Alzheimer's disease by selectively targeting the toxic oligomers...
Product Name : PMN310
Product Type : Antibody
Upfront Cash : Undisclosed
August 21, 2023
Lead Product(s) : PMN310
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Affinity Asset Advisors
Deal Size : $20.4 million
Deal Type : Private Placement
Lead Product(s) : PMN310
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : BTIG
Deal Size : $20.4 million
Deal Type : Private Placement
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
Details : The proceeds will be used to advance the clinical development of ProMIS’ lead therapeutic candidate, PMN310, a monoclonal therapeutic antibody designed for the treatment of Alzheimer's disease (AD).
Product Name : PMN310
Product Type : Antibody
Upfront Cash : Undisclosed
August 09, 2023
Lead Product(s) : PMN310
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : BTIG
Deal Size : $20.4 million
Deal Type : Private Placement
Lead Product(s) : PMN310
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) that are believed to be a major driver of alzheimer’s disease.
Product Name : PMN310
Product Type : Antibody
Upfront Cash : Inapplicable
August 05, 2023
Lead Product(s) : PMN310
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Karolinska University Hospital
Deal Size : $2.0 million
Deal Type : Agreement
Details : The agreement aims to investigate the use of IntelGenx’s Montelukast VersaFilm, a leukotriene receptor antagonist, for the treatment of Parkinson’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 25, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Karolinska University Hospital
Deal Size : $2.0 million
Deal Type : Agreement
Lead Product(s) : Lucid-21-302
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.
Product Name : Lucid-MS
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 02, 2023
Lead Product(s) : Lucid-21-302
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine,Midomafetamine
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety eff...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 02, 2023
Lead Product(s) : Psilocybine,Midomafetamine
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rotigotine
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rotigotine transdermal patch is a non-ergoline dopamine agonist for the treatment of Parkinson's disease and restless legs syndrome (RLS) in Europe and the United States.
Product Name : ROV045
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : Rotigotine
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable